Interview with Howard Sui, Managing Director, Merck Serono China
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
Address: 10F, Tower B, Gemdal Plaza,
No.91 Jianguo Road,
Chaoyang District,
100022 Beijing,
P.R. China
Tel: +86-10-5907-2688
Web: http://www.merck-china.com/en/pharmaceuticals/pharmaceuticals.html
Merck Group in China is the sales organization of the globally operating group Merck KGaA, Darmstadt (Germany) and provides the Chinese market with high-quality pharmaceutical and chemical products. In fact, Merck initiated its business in China as early as 1900. One hundred years later, Merck is represented in the most developed cities in China, including Hong Kong.
Cardiovascular, thyroid, surgical, growth hormone and anti-allergy, women’s health and fertility, neurodegenerative diseases and oncology
As growth has stalled in Europe, the US and Japan, many multinational companies are looking at China as part of a hedging strategy and a key growth driver of the…
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment…
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the…
Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market. Unmet medical needs…
Dr Yi (York) Chen, VP for operations and commercial planning at Arctic Vision shares his priorities, his wide experience of ophthalmology product launches in China, and how the company is…
Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early…
A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine…
See our Cookie Privacy Policy Here